---
document_datetime: 2025-06-11 09:29:23
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/zostavax-epar-procedural-steps-taken-authorisation_en.pdf
document_name: zostavax-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4285365
conversion_datetime: 2025-12-27 13:45:37.497803
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1 Submission of the dossier

The  Applicant  Sanofi  Pasteur  MSD  submitted  on  26  May  2005  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Zostavax,  through  the  centralised procedure. The eligibility to the centralised procedure was agreed upon on 16 September 2004.

- The  European  Commission  granted  a  marketing  authorisation  valid  throughout  the  European Union for  Zostavax on 19 May 2006.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Manfred Haase Co-Rapporteur: Pekka Kurki Scientific Advice: The applicant did not seek scientific advice at the CHMP. Licensing status: The product was not licensed in any country at the time of submission of the application. 2 Steps taken for the assessment of the product · The application was received by the EMEA on 26 May 2005. · The procedure started on 15 June 2005. · The Rapporteur's first Assessment Report was circulated to all  CHMP  members  on 1 September 2005. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 30 August 2005. · During  the  meeting  on  10-13  October  2005,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 14 October 2005. · The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 18 November 2005. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 2 January 2006. · The  Biologics  Working  Party  during  its  meeting  of  17-18  January  2006  adopted  the  BWP Report to be transmitted to the CHMP for endorsement. · During the CHMP meeting on 23-25 January 2006, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant. · The applicant submitted the responses to the CHMP  list of outstanding issues on 8 February 2006. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of outstanding issues to all CHMP members on 14 February 2006. · The  Biologics  Working  Party  during  its  meeting  of  13-15  February  2006  adopted  the  BWP Report to be transmitted to the CHMP for endorsement. · During the meeting on 20-23 February 2006, outstanding issues were addressed by the applicant during a hearing before the CHMP. · During the meeting on 20-23 March 2006, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Zostavax on 23 March 2006. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 22 March 2006. Medicinal product no longer authorised